<List><item><source>MED</source><extId>29034095</extId><pmcid>PMC5629772</pmcid><annotations><annotation><prefix>escriptionETPhase II</prefix><exact>NCT02289560</exact><postfix> – multi-centered,</postfix><tags><tag><name>NCT02289560</name><uri>http://identifiers.org/clinicaltrials/NCT02289560</uri></tag></tags><id>http://europepmc.org/articles/PMC5629772#europepmc-be0e443169e9b467407f887ea5f2d5da</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>k at efficacy for ET</prefix><exact>NCT01827904</exact><postfix> - prospective, rand</postfix><tags><tag><name>NCT01827904</name><uri>http://identifiers.org/clinicaltrials/NCT01827904</uri></tag></tags><id>http://europepmc.org/articles/PMC5629772#europepmc-b23e424d0fc997d4ce2e8f974cd2ab21</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>rate safetyPDPhase I</prefix><exact>NCT02347254</exact><postfix>, NCT01772693, NCT02</postfix><tags><tag><name>NCT02347254</name><uri>http://identifiers.org/clinicaltrials/NCT02347254</uri></tag></tags><id>http://europepmc.org/articles/PMC5629772#europepmc-d1a8cbac698fb08b79a44272cfa58dc5</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>Phase INCT02347254, </prefix><exact>NCT01772693</exact><postfix>, NCT02263885, NCT02</postfix><tags><tag><name>NCT01772693</name><uri>http://identifiers.org/clinicaltrials/NCT01772693</uri></tag></tags><id>http://europepmc.org/articles/PMC5629772#europepmc-7dca69d1d96b19ce583975dbc82c25ac</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>47254, NCT01772693, </prefix><exact>NCT02263885</exact><postfix>, NCT02246374, NCT02</postfix><tags><tag><name>NCT02263885</name><uri>http://identifiers.org/clinicaltrials/NCT02263885</uri></tag></tags><id>http://europepmc.org/articles/PMC5629772#europepmc-2ef2838e57a2b0ed8b72f7b4d2d54e0d</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>72693, NCT02263885, </prefix><exact>NCT02246374</exact><postfix>, NCT02252380 - phas</postfix><tags><tag><name>NCT02246374</name><uri>http://identifiers.org/clinicaltrials/NCT02246374</uri></tag></tags><id>http://europepmc.org/articles/PMC5629772#europepmc-51d672d4e4141ab47a19591a69e3a71c</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>63885, NCT02246374, </prefix><exact>NCT02252380</exact><postfix> - phase I trial to </postfix><tags><tag><name>NCT02252380</name><uri>http://identifiers.org/clinicaltrials/NCT02252380</uri></tag></tags><id>http://europepmc.org/articles/PMC5629772#europepmc-65a4ce470361b81972adaa26ce833874</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix> – ablationPhase I</prefix><exact>NCT00147056</exact><postfix>, NCT02343991, NCT01</postfix><tags><tag><name>NCT00147056</name><uri>http://identifiers.org/clinicaltrials/NCT00147056</uri></tag></tags><id>http://europepmc.org/articles/PMC5629772#europepmc-40db9d28f9cdee22f4f097056033d4d4</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>Phase INCT00147056, </prefix><exact>NCT02343991</exact><postfix>, NCT01473485 – ph</postfix><tags><tag><name>NCT02343991</name><uri>http://identifiers.org/clinicaltrials/NCT02343991</uri></tag></tags><id>http://europepmc.org/articles/PMC5629772#europepmc-812c7b9c8f7fe67a7f12c6e3a40495e1</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>47056, NCT02343991, </prefix><exact>NCT01473485</exact><postfix> – phase I trial f</postfix><tags><tag><name>NCT01473485</name><uri>http://identifiers.org/clinicaltrials/NCT01473485</uri></tag></tags><id>http://europepmc.org/articles/PMC5629772#europepmc-27b9e1556797bdc8b8222524ed037817</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>or ablation, ongoing</prefix><exact>NCT01698437</exact><postfix> – phase I trial f</postfix><tags><tag><name>NCT01698437</name><uri>http://identifiers.org/clinicaltrials/NCT01698437</uri></tag></tags><id>http://europepmc.org/articles/PMC5629772#europepmc-ccb143a2a3dff1d933816ac18f78e409</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>BB disruptionPhase I</prefix><exact>NCT02343991</exact><postfix> – phase I trial t</postfix><tags><tag><name>NCT02343991</name><uri>http://identifiers.org/clinicaltrials/NCT02343991</uri></tag></tags><id>http://europepmc.org/articles/PMC5629772#europepmc-3d9b92296ab79876b0c1609a351e2271</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>ssion/anxietyPhase I</prefix><exact>NCT02348411</exact><postfix> – phase I trial t</postfix><tags><tag><name>NCT02348411</name><uri>http://identifiers.org/clinicaltrials/NCT02348411</uri></tag></tags><id>http://europepmc.org/articles/PMC5629772#europepmc-e6af27d84dc60fe6277b152bef40f563</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>ation-refractory MDD</prefix><exact>NCT02685488</exact><postfix> – phase I trial o</postfix><tags><tag><name>NCT02685488</name><uri>http://identifiers.org/clinicaltrials/NCT02685488</uri></tag></tags><id>http://europepmc.org/articles/PMC5629772#europepmc-c51948475a3eaec1e04f00a7e1842cb8</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>depressionOCDPhase I</prefix><exact>NCT01986296</exact><postfix> - phase I trial of </postfix><tags><tag><name>NCT01986296</name><uri>http://identifiers.org/clinicaltrials/NCT01986296</uri></tag></tags><id>http://europepmc.org/articles/PMC5629772#europepmc-7101c4e35298922ea1ed72f71b85c612</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>te cortex sonication</prefix><exact>NCT03156335</exact><postfix> - phase I trial to </postfix><tags><tag><name>NCT03156335</name><uri>http://identifiers.org/clinicaltrials/NCT03156335</uri></tag></tags><id>http://europepmc.org/articles/PMC5629772#europepmc-6c8178220c3ed048cdb19219e98f7d57</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>ain syndromesPhase I</prefix><exact>NCT01699477</exact><postfix> - phase I trial of </postfix><tags><tag><name>NCT01699477</name><uri>http://identifiers.org/clinicaltrials/NCT01699477</uri></tag></tags><id>http://europepmc.org/articles/PMC5629772#europepmc-8151fd03e26d8d07d3b00c6225a8683c</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>osurgery Focus 2012)</prefix><exact>NCT03111277</exact><postfix> - phase I trial for</postfix><tags><tag><name>NCT03111277</name><uri>http://identifiers.org/clinicaltrials/NCT03111277</uri></tag></tags><id>http://europepmc.org/articles/PMC5629772#europepmc-a02ebfcdf3b26818e1289d9c29b60a9b</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix> – ablationPhase I</prefix><exact>NCT02804230</exact><postfix> – phase I trial, </postfix><tags><tag><name>NCT02804230</name><uri>http://identifiers.org/clinicaltrials/NCT02804230</uri></tag></tags><id>http://europepmc.org/articles/PMC5629772#europepmc-a4caf9d3cf5a42e7c0512beb5f048d6e</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>uromodulationPhase I</prefix><exact>NCT02151175</exact><postfix> – phase I trial, </postfix><tags><tag><name>NCT02151175</name><uri>http://identifiers.org/clinicaltrials/NCT02151175</uri></tag></tags><id>http://europepmc.org/articles/PMC5629772#europepmc-e0d6448c3ecb1bf1a9fc3b8c4cdb4f5b</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>mporal lobeADPhase I</prefix><exact>NCT02986932</exact><postfix> – phase I trial o</postfix><tags><tag><name>NCT02986932</name><uri>http://identifiers.org/clinicaltrials/NCT02986932</uri></tag></tags><id>http://europepmc.org/articles/PMC5629772#europepmc-cf3cdfa79e5b8be513271c95970a0eaf</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>US thalamotomy for neuropathic pain (</prefix><exact>NCT01699477</exact><postfix>). </postfix><tags><tag><name>NCT01699477</name><uri>http://identifiers.org/clinicaltrials/NCT01699477</uri></tag></tags><id>http://europepmc.org/articles/PMC5629772#europepmc-2076ab5bff9bef961fd6eb5c8c10e7c3</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>wo clinical trials (</prefix><exact>NCT02348411</exact><postfix>, NCT02685488) are c</postfix><tags><tag><name>NCT02348411</name><uri>http://identifiers.org/clinicaltrials/NCT02348411</uri></tag></tags><id>http://europepmc.org/articles/PMC5629772#europepmc-a709f752963cefabbf5cb1a80f0be273</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>rials (NCT02348411, </prefix><exact>NCT02685488</exact><postfix>) are currently unde</postfix><tags><tag><name>NCT02685488</name><uri>http://identifiers.org/clinicaltrials/NCT02685488</uri></tag></tags><id>http://europepmc.org/articles/PMC5629772#europepmc-321262dae3fb8a8d2db5345489ac2849</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>tly phase I trials (</prefix><exact>NCT01698437</exact><postfix>, NCT00147056, NCT01</postfix><tags><tag><name>NCT01698437</name><uri>http://identifiers.org/clinicaltrials/NCT01698437</uri></tag></tags><id>http://europepmc.org/articles/PMC5629772#europepmc-513279aceda53fb3b6aa01582b59ece3</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>rials (NCT01698437, </prefix><exact>NCT00147056</exact><postfix>, NCT01473485) are u</postfix><tags><tag><name>NCT00147056</name><uri>http://identifiers.org/clinicaltrials/NCT00147056</uri></tag></tags><id>http://europepmc.org/articles/PMC5629772#europepmc-d11cfed17dac35b8319c2ae5aad43df4</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>98437, NCT00147056, </prefix><exact>NCT01473485</exact><postfix>) are underway with </postfix><tags><tag><name>NCT01473485</name><uri>http://identifiers.org/clinicaltrials/NCT01473485</uri></tag></tags><id>http://europepmc.org/articles/PMC5629772#europepmc-c71d2d6f94fd409b971298180c5f636c</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>h high-grade gliomas to deliver TMZ (</prefix><exact>NCT02343991</exact><postfix>). </postfix><tags><tag><name>NCT02343991</name><uri>http://identifiers.org/clinicaltrials/NCT02343991</uri></tag></tags><id>http://europepmc.org/articles/PMC5629772#europepmc-f5247f9525c9baeb58a3c33253c50b20</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>nts with mild Alzheimer’s disease (</prefix><exact>NCT02986932</exact><postfix>). </postfix><tags><tag><name>NCT02986932</name><uri>http://identifiers.org/clinicaltrials/NCT02986932</uri></tag></tags><id>http://europepmc.org/articles/PMC5629772#europepmc-f904a465a7363ad937350a50612843aa</id><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation></annotations></item></List>